We already know that low-dose CT is a valuable tool for reducing mortality rates, but now there’s evidence that it might reduce financial costs as well. A new analysis of the 2010 National Lung Screening Trial (NLST) shows that low-dose CT is a cost-effective diagnostic tool for patients at high-risk of lung cancer, according to AuntMinnie.com.
The Medical Imaging and Technology Alliance (MITA) released a statement saying the organization welcomes the analysis and “looks forward to ongoing collaboration with patient advocates and others in the imaging community to ensure access to this lifesaving technology.”
In my opinion, though, the key question in whether low-dose screening for lung cancer is cost effective is: what is the cost of working up the false positives? That cost needs to be subtracted from the cost benefit of the lives saved. This new analysis suggests that low-dose screening is indeed cost effective. One thing no cost analysis considers: the value of a negative exam to a very worried patient.
Further new twist: we now can do ultra-low-dose lung cancer screening using fully model-based iterative reconstruction techniques. This technique enables a 60 percent radiation dose reduction (down to the sub-0.5 mSv range) below that of even recent low-dose CT – further substantially decreasing any downside from lung cancer screening in high-risk patients.